Company
4basebio PLC
Headquarters: Cambridge, United Kingdom
Employees: 21
CEO: Dr. Heikki Lanckriet Ph.D.
Market Cap
£196.3 Million
GBP as of July 1, 2024
US$248.3 Million
4basebio PLC Categories
United Kingdom Healthcare BiotechnologyUnited Kingdom Healthcare United Kingdom Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
4basebio UK Societas develops gene therapy technologies and solutions primarily in the United Kingdom. It focuses on the manufacture and supply of synthetic DNA and non-viral nanoparticles for research, therapeutic, and pharmacological use. The company provides services for biotech and pharma customers in the gene therapy and gene vaccine development. It is also involved in the manufacture of enzymes that are used for diagnostic and laboratory test kits. The company was formerly known as 4Basebio SE and changed its name to 4basebio UK Societas in December 2020. 4basebio UK Societas was incorporated in 2020 and is based in Cambridge, United Kingdom.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
4basebio PLC has the following listings and related stock indices.
Stock: LSE: 4BB wb_incandescent
Stock: FSX: 88Q wb_incandescent